Symbols

ABEO

Abeona Therapeutics·NASDAQ

--(--)

ABEO fundamentals

ABEO Q4 2025 Earnings

Abeona Therapeutics (ABEO) released its earnings on Mar 17, 2026: revenue was 3.76M (YoY --), missed estimates; EPS was -0.36 (YoY -172.00%), missed estimates.

Revenue / YoY

3.76M

EPS / YoY

-0.36

-172.00%

Report date

Mar 17, 2026

ABEO Earnings Call Summary for Q4,2025

Commercial Momentum: 2 treated, 3 biopsied, 10 in Q2 pipeline; 7 QTCs by year-end.
Financial Strength: $191M cash, $152M voucher sale, $5.8M 2025 revenue.
Profitability Target: 3-4 patients/month to break even.
Payer Support: 80% commercial coverage, no denials yet.
Manufacturing Scale: 6/month now, 10/month by H2.

Earnings

EPS

Revenue

Revenue & Expenses

ABEO has released its 2025 Q4 earnings report, with revenue of 5.42M, reflecting a YoY change of NaN%, and net profit of -20.46M, showing a YoY change of -120.17%. The Sankey diagram below clearly presents ABEO's revenue sources and cost distribution.

Key Indicators

Abeona Therapeutics (ABEO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Abeona Therapeutics (ABEO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Abeona Therapeutics (ABEO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Abeona Therapeutics (ABEO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown